drugset

drugset / Trial / NCT00879242

Effect of Deferasirox on Patients With Cardiac MRI T2* < 20 Msec

NCT00879242 ↗

Phase 2 Completed 20 enrolled Novartis Pharmaceuticals

NaSingle-groupOpen-labelTreatment

Summary

This study will assess the safety and efficacy of deferasirox in patients with cardiac MRI T2\* \< 20 msec.

Timeline

Start: 2009-02
Primary completion: 2011-05
Completion: —

Publications

Results Piga A, Longo F, Origa R, Roggero S, Pinna F, Zappu A, Castiglioni C, Cappellini MD. Deferasirox for cardiac siderosis in beta-thalassaemia major: a multicentre, open label, prospective study. Br J Haematol. 2014 Nov;167(3):423-6. doi: 10.1111/bjh.12987. Epub 2014 Jun 30. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Deferasirox	Unknown	30 mg/kg	Oral
Subject	Deferasirox	Unknown	40 mg/kg	Oral

Indications